• iJET Awarded ISO 27001 Certification for Information Security Management
    Demonstrates Commitment to Data Security with Enterprise-wide Certification
  • iJET International Announces red24 Acquisition
    iJET Continues its Global Growth Strategy with its Second Acquisition in 2016
  • iJET’s industry-leading intelligence and Worldcue® Risk Platform

    Protect your people and save time and costs with actionable intelligence

  • iJET's Global Integrated Operations Center

    Get a closer look at how iJET supports clients

Forward

The current outbreak of yellow fever in Brazil, has also strained existing stock, and Sanofi Pasteur, the manufacturer of yellow fever vaccine, has announced that once exhausted, no additional product will be available until mid-2018. Given the anticipated critical shortage, the US Food and Drug Administration (FDA) has approved the use of an alternate vaccine; Stamaril, to protect against this disease. Stamaril, available in Europe, had not previously been used for US residents and is considered “experimental” by US authorities.

Latest Tweets